导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.16% | 962/4773 |
| 近一周 | -1.34% | 1055/5458 |
| 近一月 | -1.32% | 1138/5421 |
| 近一季 | 3.14% | 426/5205 |
| 近半年 | 0.11% | 1328/4920 |
| 近一年 | 9.67% | 1116/4361 |
| 近两年 | 51.70% | 1444/2954 |
| 近三年 | 25.61% | 1264/2253 |
| 成立以来 | 84.71% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.21% 1011/4961 |
0.53% 3168/5312 |
- - |
- - |
| 2025 | 16.75% 2417/4813 |
1.70% 1569/3635 |
0.96% 2516/4076 |
10.54% 3279/4524 |
2.86% 822/4813 |
| 2024 | 6.99% 1701/3463 |
0.32% 999/2808 |
-3.42% 1368/3014 |
10.42% 2623/3129 |
- 1287/3463 |
| 2023 | -5.76% 775/2656 |
8.30% 470/2280 |
-1.74% 522/2385 |
-5.75% 1368/2515 |
-6.05% 1611/2655 |
| 2022 | -19.05% 794/2207 |
-14.47% 949/1919 |
6.54% 676/2016 |
-10.93% 471/2113 |
-0.27% 1585/2208 |
| 2021 | 13.10% 368/1822 |
-4.01% 845/1255 |
10.00% 500/1330 |
8.74% 154/1466 |
-1.50% 1370/1822 |
| 2020 | 39.73% 327/1250 |
-3.71% 317/1028 |
24.66% 167/1067 |
11.78% 426/1164 |
4.14% 864/1184 |
| 2019 | 49.12% 108/1092 |
32.84% 156/739 |
-5.15% 450/788 |
6.31% 130/850 |
11.33% 63/918 |
| 2018 | -28.12% 435/834 |
- - |
-11.64% 368/631 |
-6.65% 411/660 |
-12.18% 420/682 |
| 2017 | 1.28% 452/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 申万菱信中证500指数增强A VS. 长安沪深300非周期A(740101) |